Yet Another UK Call For Views On What Brexit Means For Pharma, Regulation & Health
Executive Summary
Another inquiry investigation into the consequences of Brexit in the life sciences area has been launched, this time by the UK House of Commons health committee. Stakeholders are asked to comment on issues like the impact on the regulation of medicines and medical devices, how to ensure continued access to medicines, and whether transitional arrangements will be needed.
You may also be interested in...
Health Cttee Asks To See ‘Secret’ Pharma Sector Reports As Distributors Warn Of Brexit Threat To UK Supply Chain
The House of Commons Health Committee wants to see the government’s confidential “sector reports” on the likely impact of Brexit in the life sciences sector. Meanwhile, drug distributors have warned of major disruptions to the medicines supply chain if border controls and tariffs are imposed in the UK, and a major industry consultancy says the UK’s position as a launch pad for companies to set up in Europe is under threat.
Regulatory Alignment Of UK With EU Post-Brexit Seen As Critical
Retain high-quality regulatory capability and the innovative leadership of the UK medicines agency, align with the EU and don’t build a stand-alone regulatory system. Those are some of the recommendations in the new and wide-ranging industry-led Life Sciences Industrial Strategy relating to the future, post-Brexit regulation of medicines in the UK.
UK Govt Issues Brexit Wish List For Pharma Regulation; Wants Lots To Stay The Same
A position paper from the UK government has laid out some ideas for ensuring a smooth transition to a post-Brexit world in the area of regulation, with a focus on issues such as marketing authorization validity, continued regulatory oversight, inspections, and adverse drug reaction reporting.